> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fidelity's Parent FMR Holds 6.4% Of Tarsus Pharmaceuticals, A Passive Stake
- URL: https://www.bullished.co/fidelitys-parent-fmr-holds-6-4-of-tarsus-pharmaceuticals-a-passive-stake-4f46bfbf/
- Published: 2026-11-05T18:54:17.000Z
- Updated: 2026-11-05T18:54:17.000Z
- Description: FMR LLC reports 3,143,158.2 Tarsus shares as of September 30, weeks after the eye-drug maker raised its 2026 Xdemvy sales outlook.
- Author: Matteo Parrino
- Tags: SEC Filings, TARS, Industry: Healthcare

FMR LLC, the parent of Fidelity, [holds 6.4%](https://www.sec.gov/Archives/edgar/data/0000315066/000031506626002878/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Tarsus Pharmaceuticals](https://www.bullished.co/tag/tars/), or 3,143,158.2 common shares as of September 30, according to a passive ownership disclosure filed with the SEC on Thursday. Tarsus, which develops and sells eye-care therapeutics led by the Demodex blepharitis drop Xdemvy, shares the news with a record sales quarter behind it.

## How Fidelity holds the shares

FMR has sole voting power over 3,139,690 of the shares and shared voting power over none. Abigail P. Johnson, FMR's chairman and CEO, is a joint reporting person and also shows 6.4%, though the filing gives her no voting power in her own name.

The [exhibit](https://www.sec.gov/Archives/edgar/data/315066/000031506626002878/exhibit99.txt?ref=bullished.co) lists the holding entities, among them FIAM, Fidelity Management & Research Company and Fidelity Management Trust Company. FMR certified that the shares were acquired and held in the ordinary course of business, not to change or influence control of Tarsus.

Tarsus shares traded at $68.00 in Thursday trading, down about 2% from the prior close of $69.07\. The company's market value was $3.4 billion.

## A record quarter for Xdemvy

Xdemvy, approved by the FDA in July 2023 and launched in the US the next month, is Tarsus's marketed product. Net sales were more than $646 million from launch through the end of 2025, according to the company's annual report.

In the third quarter, Tarsus [reported record Xdemvy sales](https://finance.yahoo.com/healthcare/articles/tarsus-pharmaceuticals-q3-earnings-call-031413368.html?ref=bullished.co) of $194.6 million, up nearly 64% from a year earlier. It raised its 2026 sales outlook to a range of $715 million to $730 million. The company still posted a net loss for the quarter and ended September with about $310 million in cash.

CEO Bobby Azamian said Tarsus has now passed $1 billion in cumulative net product sales of Xdemvy since launch.

## Pipeline readouts due in 2027

The company uses the same active ingredient, lotilaner, in candidates for ocular rosacea and Lyme disease prevention. Tarsus expects top-line data from both programs in the first half of 2027.

Top-line results from the ocular rosacea and Lyme disease prevention programs are due in the first half of 2027.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — FMR LLC re: TARSUS PHARMACEUTICALS INC (TARS)](https://www.sec.gov/Archives/edgar/data/0000315066/000031506626002878/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 99](https://www.sec.gov/Archives/edgar/data/315066/000031506626002878/exhibit99.txt?ref=bullished.co) — SEC EDGAR
- [Tarsus Pharmaceuticals Inc (TARS) (Q3 2026) Earnings Call Highlights: Record Xtendi Sales and ...](https://finance.yahoo.com/healthcare/articles/tarsus-pharmaceuticals-inc-tars-q3-030455767.html?ref=bullished.co) — Yahoo Finance
- [Tarsus Pharmaceuticals Q3 Earnings Call Highlights](https://finance.yahoo.com/healthcare/articles/tarsus-pharmaceuticals-q3-earnings-call-031413368.html?ref=bullished.co) — Yahoo Finance
- [Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates](https://nz.finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-reports-235509435.html?ref=bullished.co) — Yahoo Finance
- [Tarsus Pharmaceuticals, Inc. GAAP EPS of -$14.40 misses by $10.38, revenue of $194.5M beats by $3.72M | Seeking Alpha](https://seekingalpha.com/news/4664242-tarsus-pharmaceuticals-inc-gaap-eps-of--1440-misses-by-1038-revenue-of-1945m-beats-by-372m?ref=bullished.co) — seekingalpha.com
- [How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%](https://finance.yahoo.com/markets/stocks/articles/much-upside-left-tarsus-pharmaceuticals-135502748.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance

### More on Tarsus Pharmaceuticals

- [Tarsus Shelves TP03 Filings In Europe And Japan, Citing Most-Favored-Nation Pricing Rules](https://www.bullished.co/tarsus-shelves-tp03-filings-in-europe-and-japan-citing-most-favored-nation-pricing-rules-13acfb87/)
- [Tarsus Expensed $632.2 Million For Two Unapproved Retina Drugs, Leaving Equity At $104 Million](https://www.bullished.co/tarsus-expensed-632-2-million-for-two-unapproved-retina-drugs-leaving-equity-at-104-4141d98d/)
- [Tarsus Books $632.2 Million Charge For Two Acquired Drugs, Swamping Record Xdemvy Sales](https://www.bullished.co/tarsus-books-632-2-million-charge-for-two-acquired-drugs-swamping-record-xdemvy-sales-2170e9f8/)

[All Tarsus Pharmaceuticals (TARS) coverage →](https://www.bullished.co/tag/tars/)